Micro RNA
MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.
- Biogenesis
- Cellular functions
- Non-coding RNAs
Related Conference of Micro RNA
20th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
18th International Conference on Human Genomics and Genomic Medicine
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Micro RNA Conference Speakers
Recommended Sessions
- Bioinformatics in Genomics
- Biomarkers
- Cancer genomics
- Cell Biology
- Clinical Genomics
- Comparative Genomics
- Functional Genomics
- Future Trends in Genomics
- Gene Editing
- Genome Medicine
- Genomics
- Human Genomics
- Micro RNA
- Microbial Genomics
- Molecular Biology
- Next Generation Sequencing
- Pharmacogenomics
- Plant Genomics and Molecular Plant Sciences
- Proteomics
- Stem Cell Biology
- Structural Biology
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)